anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND AND OBJECTIVES: Despite the fact that the parietal cortex is associated with consciousness, the underlying mechanisms of parietal repetitive transcranial magnetic stimulation (rTMS) have not yet been specifically investigated. The present study aims to examine the effects of parietal rTMS on patients with disorders of consciousness (DoC) and identify a novel potential target.
METHODS: Twenty minimally conscious state (MCS) patients were stochastically assigned to a real or sham rTMS group in a controlled trial. The real rTMS group was administered over the parietal cortex, with a frequency of 10 Hz and a rest motor threshold of 90 %. The sham rTMS group was identical to the real rTMS group without magnetic stimulation over the cortex. Pre- and post-treatment resting-state electrophysiological (EEG) data and coma recovery scale-revised (CRS-R) score were gathered. Microstate analyses were calculated to evaluate the brain activity dynamics.
RESULTS: The real rTMS treatment improved the CRS-R scores. There were notable alterations in the mean microstate duration (MMD) of microstate B in the real rTMS group. The sham rTMS group did not exhibit such changes in CRS-R score or EEG results, which were not statistically significant. Furthermore, the MMD and RTC of microstate E were found to be negatively correlated with baseline CRS-R scores.
CONCLUSION: Parietal rTMS can induce behavioral improvement and brain activity dynamics in patients with MCS. EEG microstates can be used as a valuable method to study neurophysiological mechanisms behind MCS. And the parietal cortex represents an alternative for rTMS therapy protocols.
During the outpatient clinic visit, an information leaflet will be given about the subjects that should be considered for prevention of SSI before surgery. 2% mupirocin ointment will be applied to the nostrils with the swab twice-daily before surgery and once on the morning of surgery. Body cleaning will be done with 4% chlorhexidine gluconate shower the night before the surgery. Prophylactic antibiotics by weight will be administered within 60 minutes of anesthesia induction. The planned aseptic technique will be applied and a strict draping will be used in the incision site. Body temperature, blood pressure, respiratory rate, heart rate and O2 saturation of the patients will be monitored every 1 hour during the operation and data will be recorded on the data collection form. Before the skin closes, the surgical site will be washed with warm Isotonic NaCl solution. Wound care education will be provided to the patient and family before discharge.
PROBLEM TO BE SOLVED: To prepare a highly safe skin preparation for external use having excellent effect without inducing any problem about toxicity, and usable as a cosmetic or a raw material of a medicine, etc. SOLUTION: This skin preparation for external use contains an extract of Eucommia ulmoides. The extract is obtained by dipping or superheat refluxing whole plant of Eucommia ulmoides containing leaves, stems and fruits together with a single or mixed solvent of water, methanol or acetone, etc., filtering and concentrating. A mixing amount of the Eucommia ulmoides extract in the skin preparation for external use may be 0.005-20.0wt.%, especially 0.01-10.0wt.% as a dried material. The skin preparation is useful as, e.g. an ointment, a cream or a lotion. The composition can protect oil and fat such as mink oil from oxidation and can effectively mix the oil and fat into a cosmetic.
PURPOSE:To obtain a hair treating agent, excellent in treatment effects and capable of sustaining the effects even after shampooing. CONSTITUTION:The hair treating agent is composed of the first agent containing 0.01-5.0wt.%, preferably 0.05-3.0wt.% polysaccharides having anionic groups dissociable in water, preferably glucuronic acid or mannuronic acid as a constituent component and the second agent containing 0.05-5.0wt.%, preferably 0.5-3.0wt.% surfactant having cationic groups dissociable in water, e.g. an alkyl- quaternary ammonium salt or an alkyl-pyridinium salt. The first and second agents are successively applied to the hair regardless of the order. Xanthan gum and hyaluronic acid containing the glucuronic acid as a constituent component and alginic acid containing the mannuronic acid as a constituent component are cited as the polysaccharides. An oil or a humectant is blended with the first and/or second agents. This treating agent can be applied as a hair dye having treatment effects by further adding a dye thereto.
The present disclosure provides a glass composition that include from about 50 mol % to about 95 mol % of B2O3; from about 5 mol % to about 50 mol % of one or more glass components selected from the group consisting of: Li2O, Rb2O, K2O, Na2O, SrO, CaO, MgO, and ZnO. The glass composition includes less than 30 mol % of Rb2O. The glass composition is a quaternary system. The glass composition is a particulate material that includes particles that are from about 1 to about 50 μm in size. The glass composition loses at least 5 mass % within 24 hours when exposed to a buffered saline solution. The glass composition may be used to desensitize dentin. The present disclosure also provides a dentin-desensitizing composition.
A product which accelerates cell growth is extracted from bone marrow as follows. Complete bone marrow is mixed with water and homogenised, mechanically or otherwise, and the aq. phase separated. A solvent is then added and the mixture stirred. It is then separated, the desired product forming a gel between the aqueous and the solvent phases. The prod. is used as a cicatrising agent. Pref. the solvent used is an antiseptic, such as ether, and the sepn. of aqueous and solvent phases is effected by centrifuging. The gel obtd. may be washed rapidly to eliminate traces of blood and mixed with a material which is impermeable to air, such as a fat, the pref. fat being that extracted from bone marrow. An anti-inflammatory and a preservative may also be incorporated.
The present application establishes a simultaneous relationship between lipoprotein and lipid metabolism by lipoprotein-lipid aggregation simultaneous groups. The schematic diagrams of lipoprotein and lipid metabolism relationship compared to cholesterol drug metabolism, and diagrams of the interaction path of blood lipid metabolism depicted by cholesterol drug metabolism. The process is through the implementation of feeding strategy refer to as architecture for the mapping relationships of equivalence variables and grade variables. Applying the descriptive statistical ratio value and the independent sample of predict variable, mapped to the mapping relationships of equivalence variables and grade variables on the mapping function of weight analysis and content analysis intensity. To this simultaneous groups grouping, perform the weight analysis intensity of the plurality of equivalence variables and content analysis intensity of the plurality of grade variables for the mapping function mapping relationship. The carrier aggregation simultaneous groups distinguish between the carrier simultaneous groups and the passenger simultaneous groups to perform multiple regression mediation. The confirmatory effectiveness and influence of simultaneous group mediation path include the effectiveness of simultaneous groups mediation path are the manipulation of the comparison to the validity of carrier group for each of a plurality of passenger groups regarding the metabolic relationships and the depiction of the validity of the metabolic interaction pathways by a plurality of the carrier aggregation. The influence of simultaneous group mediation path is the manipulation of the carrier aggregation for each of a plurality of the independent variables affects the respective dependent variables and the direction of the carrier aggregation of a plurality of regression paths.
Participants will receive faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit will take place at Week 36.
There will be 2 sessions per week for 12 weeks. Each session includes 1 hour exercise (including 5-10 minute warm-up and cool-down routine, 20-30 minute chair-based resistance exercises using Thera-Bands for muscle groups in both the upper and lower body, and 20-30 minutes aerobic exercises); and 1 hour game training using computer video games, board games and card games. Nutrition education will be given to the subjects based on their weight status. The 1st level of nutrition information (healthy eating tips for frailty prevention and management) will be given to all subjects on regular basis during the 12-week study period via short videos, text messages or Whatsapp reminders. On top of the 1st level nutrition information, 3 nutrition heath talks (1-1.5 hours per talk) about weight management will be given to those with BMI \>=25 kg/m2, and/or waist circumference \>=90 cm (male) or \>=80 cm (female) during the 12-week study period.
PURPOSE:The titled pharmaceutical containing Gleditschia japonica Miquel and Quillaia saponaria Molia as active constituents. CONSTITUTION:A skin keratin or epithelial softener obtained by extracting Gledistchia japonica Miquel of the subfamily Caesalpinioidase of the family Leguminosae and Quillaia saponaria Molina which is high tree of the famil Rosaceae in the raw state or dried plant with a polar solvent, e.g. ethanol, and incorporating the resultant extract as active constituents. The amount of the dried powder to be incorporated is 2-60wt% preferably 5-40wt% based on the base (particularly pod for Gleditschia japonica Miquel and bark for Quillaia saponaria Molina). When the extract is incorporated, the amount thereof is 1-50wt%, preferably 2-30wt%. If the dried powder and the extract are used in a mixture, the Ouillaia saponaria Molina is preferably used in an amount of 0.1-10 times based on 1pts.wt. Gleditschia japonica Miquel. Examples of the dosage form include cataplasma, ointment, solution, tacky application agent, etc. The incorporation of salicylic acid has synergistic effect and the addition of 2-50wt%, preferably 10-50wt% based on the active constituent, as necessary, is further effective.
Cisplatin 25mg/sq.m. at day 1 + 8 and Gemcitabine 1000 mg/sq.m. at day 1 + 8. Cycle will be repeated every 3 weeks.
1356911 Purification and functionation of carcinoembryonic antigen F HOFFMANN-LA ROCHE & CO AG 1 June 1971 [1 June 1970 27 Jan 1971 12 April 1971] 18309/71 Heading A5B A purified human carcinoembryonic antigen is prepared by a process comprising: a) homogenizing adenocarcinoma tissue; b) removing solid from the homogenisate; c) treating the supernatant with a glycoprotein solvent (e.g. perchloric acid); d) discarding the precipitate and clarifying the solution; c) subjecting the clarified solution to osmosis against an aqueous solution of a polyethylene glycol which has a M.W. of approx. 15,000 to 20,000 and a softening point of about 60C; f) dissolving the resulting rentate in an aqueous buffer of pH 5-9; g) chromatographing the solution from f) sequentially on two different gel columns, the one being an agarose gel comprising approximately 6% agarose and having a particle size of 40-210 microns and the other being a water-insoluble, cross-linked, hydrophilic, dextran polymer gel; h) collecting the fractions having a spectrophotometric adsorption peak of 280mÁ and a M.W. of about 200,000 to about 500,000. These fractions may be combined and subjected to further treatment to produce two different active compounds, namely "Human carcinoembryonic antigen A and B". Suitable treatment comprises osmosis against a polyethylene glycol solution as described above, dissolution in a buffer, e.g. ammonium acetate at pH4, clarification and chromatography on a mixed bed ion-exchange column comprising microgranular diethylaminoethyl cellulose and carboxymethyl cellulose, using e.g. ammonium acetate/sodium chloride (pH 4) as eluant.
Following randomisation each couple will be given one set of 7 condoms as per randomisation schedule. Couples will return to the clinic site for collection of their next set of condoms on two additional occasions. Each couple will test a maximum of 21 condoms during their participation in the investigation.
OBJECTIVES: I. Determine the efficacy of interferon alfa-2b in reducing the relapse rate in patients with recurrent or refractory Hodgkin's disease or non-Hodgkin's lymphoma in second remission following high dose chemotherapy and autologous stem cell transplantation. II. Compare the time to disease progression and survival in this patient population treated with interferon alfa-2b vs no further treatment. III. Assess the tolerability of these treatment regimens in these patients.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to lymphoma subtype. Patients are randomized to one of two treatment arms. Arm I: Patients receive no further therapy following high dose chemotherapy and autologous stem cell transplantation. Arm II: Beginning 4 weeks after high dose chemotherapy and autologous stem cell transplantation, patients receive interferon alfa-2b subcutaneously three times a week. Treatment continues for 18 months in the absence of disease progression or unacceptable toxicity. Patients are followed every 6 months until disease progression.

PROJECTED ACCRUAL: A total of 360 patients (180 per treatment arm) will be accrued for this study within 4-5 years.
IUD insertion and endometrial biopsies are commonly performed in office procedures that use a tenaculum to stabilize the cervix. Patient's often complain that tenaculum placement is one of the most uncomfortable parts of these procedures. Patient's who agree to be in the study will be randomized into one of two groups, either slow tenaculum placement or fast tenaculum placement. Throughout the procedure patient's will be asked to rate the amount of pain they are experiencing using a visual analog scale. The researchers will then compare the two groups. The providers will also rate what they perceived the patient's pain to be with the procedure.
Depression affects up to 40% of homebound seniors. The purpose of this research project is to assess the feasibility, acceptability, and preliminary effects of a novel internet-based cognitive behavioral therapy (iCBT) program called Empower@Home. Our team developed Empower@Home collaboratively with older adult stakeholders and social service providers. It is the first iCBT program tailored for low-income racially diverse homebound seniors. It has the potential to reduce access barriers to mental health services among this high-need population. Although Empower@Home is based on an evidence-based mental health treatment (i.e., CBT), it is a novel intervention and has not yet been tested with human subjects. This is a pilot study that involves testing the feasibility, acceptability, and preliminary effects of the intervention with a single group of participants in an open trial. No randomization will occur. All eligible participants who consent will receive the intervention. A total of15 older adults will be recruited to participate in this study. All of them will be recruited through referrals from 2 to 3 social service agencies on this list (The Information Center, Region 2 Area Agency on Aging (AAA), Senior Resources, and A \& D home care). The intervention involves attending up to 10 pre-recorded online therapy sessions and receiving weekly maintenance calls from trained research assistants for up to 12 weeks. Participants will engage in therapy at their private homes. A comprehensive baseline and post-test will be administered either over the phone or via an online survey, depending on the participants' preference. No in-person interaction between the participants and the research team is anticipated during the active treatment phase unless intervention is warranted for subjects' safety. Quantitative and qualitative data will be collected and analyzed.
The present invention relates to a monitoring system for an automatic external defibrillator, comprising: an accommodation case which has an automatic external defibrillator having a status display unit for showing normal operations and battery statuses accommodated therein and has a door unit therein; a photographing unit which is installed in the accommodation case to photograph the status display unit; and a control unit which receives photographing information from the photographing unit to collect and determine status information of the automatic external defibrillator. According to the present invention, the system photographs the status display unit of the automatic external defibrillator to determine the status information and stores and confirms the information in a server. In addition, according to the present invention, the system can generate an alert when a door is open and transmit information on whether the door is open or not to the server. Moreover, according to the present invention, a wireless charging battery is provided to supply power when a battery of the automatic external defibrillator is run out. Furthermore, according to the present invention, the status information of the automatic external defibrillator and environmental information of the inside of the accommodation case can be confirmed through an external display. In addition, according to the present invention, the status of the automatic external defibrillator at night can be confirmed. Moreover, according to the present invention, when the door is open and the automatic external defibrillator is used, the system is connected to an expert to receive an assistance and keeps the door open to photograph the site and transmit the same.
Consumption of 0.05 mg placebo/kg b.w. through capsules (once a day) by 7 days in the morning.
Patients who receive PO Rifaximin 500mg TDS for 2 weeks. All patients will receive treatment to evaluate the effect of the intervention. This is a single-arm study.
Hepatic stellate cell (HSC) activation is a crucial step in the development of liver fibrosis. Previous studies have shown that antler stem cells (AnSCs) inhibited HSC activation, suggesting that this may be achieved through secreting or releasing peptides. This study aimed to investigate whether AnSC-derived peptides (AnSC-P) could reduce liver fibrosis. The results showed that AnSC-P effectively reduced liver fibrosis in rats. Furthermore, we found that thymosin β10 (Tβ-10) was rich in AnSC-P, which may be the main component of AnSC-P contributing to the reduction in liver fibrosis. A further study showed that Tβ-10 reduced liver fibrosis in rats, with a reduction in HYP and MDA levels in the liver tissues, a decrease in the serum levels of ALP, ALT, AST, and TBIL and an increase in TP and ALB. Moreover, Tβ-10 decreased the expression levels of the genes related to the TGF-β/SMAD signaling pathway in vivo. In addition, Tβ-10 also inhibited TGF-β1-induced HSC activation and decreased the expression levels of the TGF-β/SMAD signaling pathway-related genes in HSCs in vitro. In conclusion, antler Tβ-10 is a potential drug candidate for the treatment of liver fibrosis, the effect of which may be achieved via inhibition of the TGFβ/SMAD signaling pathway.
The present invention relates to a taxol vesicle injection and a preparing method thereof. The vesicle injection is composed of taxol and auxiliary materials. The used auxiliary materials comprise SPC (granulesten), PVPk15 (polyvidone k15) or PVPk30 (polyvidone k30), F68 (poloxamer 188), PEG400 (polyethyleneglycol-400 for injection), 1, 2-propanediol(for injection) and ethanol (for injection). The vesicle injection the vesicle of which is smaller than 200 nm is prepared by compounding and emulsifying the taxol and the auxiliary materials. The medicine carrying quantity of the vesicle injection (the taxol) is from 5 mg/ ml of injection to 50 mg / ml of injection. The preparing method of the present invention is suitable for industrialized production.
NEW MATERIAL:A cyclocondensation quinone derivative shown by formula I (R<1>, R<2> and R<3> are H, methyl or methoxy; R<4> is hydroxymethyl or carboxyl which may be amidated or esterified; X is H, halogen, lower alkyl or methoxy; Y is CH2 or O) or a hydroquinone derivative thereof. EXAMPLE:1,2,3,4-Tetrahydro-4-(3,4-dimethoxy-6-methyl-2,5-benzoquinonyl )-2- naphthoic acid. USE:A drug useful for improving and treating diseases based on organic disorder in the brain. A small of the drug is orally administered. Low toxicity. PREPARATION:For example, a substituted benzaldehyde is reacted with succinic anhydride to give a butyrolactonecarboxylic acid derivative shown by formula II, which is esterified, reduced and then subjected to ring closure to give a tetralone derivative shown by formula IV. This derivative is reduced and treated with a dehydrating condensation agent to give a lactone shown by formula VI, which is condensed with a hydroquinone derivative shown by formula VII to give a compound shown by formula I wherein Y=CH2.
Adalimumab 40 mg or 80 mg subcutaneously (SC) administered every other week (eow) until approval of adalimumab for Ankylosing Spondylitis (AS) in Japan. All subjects received 40 mg of adalimumab SC eow at Baseline. The subjects who completed 16 weeks of therapy and who failed to achieve Assessments in Ankylosing Spondylitis 20 (ASAS 20) response on or after Week 16, could increase the dose of adalimumab to 80 mg eow. When the dose was increased, the higher dose was to be continued during the rest of the study.
A skin care formulation comprising azelaic acid. The skin care formulation also includes a first booster composition including at least one first active booster ingredient. The skin care formulation also includes a second booster composition that includes at least one second active booster ingredient. The skin care formulation is a water-based emulsion that remains stable for at least 3 months. A method of forming a skin care formulation comprising combining an anti-acne promoter composition, a first promoter composition, a second promoter composition, and an aqueous base composition to form the skin care formulation. The anti-acne promoter composition comprises azelaic acid.
BACKGROUND: It is unclear whether abdominal adiposity has an additional effect on post-stroke outcomes. This study aimed to determine whether waist circumference (WC) is independently associated with clinical outcomes after acute ischemic stroke.
METHODS: We enrolled patients with acute ischemic stroke from a multicenter hospital-based stroke registry in Fukuoka, Japan. We measured WC on admission and categorized patients into four groups (Q1-Q4) according to the quartiles in females and males. The clinical outcomes were poor functional outcome (modified Rankin scale score 2-6) and death from any cause. Logistic regression analysis was performed to estimate the odds ratio and 95% confidence interval of the outcomes of interest after adjusting for potential confounding factors, including body mass index (BMI).
RESULTS: A total of 11,989 patients (70.3±12.2 years, females: 36.1%) were included in the analysis. The risk of poor functional outcome significantly decreased for Q2-Q4 (vs. Q1) at discharge and Q2-Q3 (vs. Q1) at 3 months, even after adjusting for potential confounders, including BMI. In contrast, adjustment of BMI eliminated the significant association between WC and all-cause death at discharge and 3 months. The association between high WC and favorable functional outcome was not affected by fasting insulin levels or homeostatic model assessment for insulin resistance and was only found in patients without diabetes (P = 0.02 for heterogeneity).
CONCLUSIONS: These findings suggest that abdominal adiposity has an additional impact on post-stroke functional outcome, independent of body weight and insulin action.